Professor Godfrey Grech is an Associate Professor at the University of Malta, focusing on oncology research, including breast, colorectal, lung and cervical cancer. In February 2021, he was awarded a 3-year fund within the Department of Pathology, to study biomarkers that are predictive of early metastatic disease in colorectal cancer research. He is highly recognized by the clinical sector and runs numerous projects in collaboration with Mater Dei Hospital, Sir Anthony Mamo Oncology Centre and International Institutions. Of note, his research led to novel predictive biomarkers in triple negative breast cancer and the optimization of a multiplex RNA-based Expression Assay to molecular classify Breast Cancer patients and characterize tumour derived exosomes and ctDNA in colorectal cancer and lung cancer. Understanding early metastatic disease in colorectal cancer led to insights on intestinal inflammation and lifestyle interventions to resolve microbiota disbalance and dysbiosis. Currently he is promoting industrial projects to multiplex and automate technologies and systems for sensitive detection of tumor-derived biomarkers in blood. In addition to a patent submitted in 2019, Prof Grech published in high quality, peer-reviewed journals (including papers in high impact journals namely Nature genetics, Frontiers Endocrinology, Tumor Biology, Nucleic Acids research, PlosOne and JoVE), and authored book chapters covering the fields of biomarkers, technology optimization, and the role of the phosphatase, PP2A in tumor progression. Prof Godfrey Grech is part of international scientific committees including the International Scientific Council of the European Group for Molecular Pathology (EMP); Global Leader at the Genomic Medicine within the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH); member of the Pharmacogenomics Working Group of the Global Genomic Medicine Consortium (G2MC); member of the European Lifestyle medicine Organisation (ELMO) and leader of the Cancer Position Paper at the European Association for Predictive, Preventive & Personalized medicine (EPMA).